Drug Patents owned by Blue Earth

1. Drug name - AXUMIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10953112 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound Nov, 2026

(4 years from now)

US9387266 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound Nov, 2026

(4 years from now)

US10010632 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound Nov, 2026

(4 years from now)

US10933147 BLUE EARTH Imaging of metastatic or recurrent cancer Dec, 2035

(13 years from now)

US10967077 BLUE EARTH Imaging of metastatic or recurrent cancer Dec, 2035

(13 years from now)

US10716868 BLUE EARTH Imaging of metastatic or recurrent cancer Dec, 2035

(13 years from now)

US10124079 BLUE EARTH Imaging of metastatic or recurrent cancer Dec, 2035

(13 years from now)

Drugs and Companies using FLUCICLOVINE F-18 ingredient

Treatment: Method of diagnosing tumors using positron emission tomography; Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
9-221mCi/ML SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.